Medical Pharmacology: Chapter 30 — Thyroid Pharmacology -- Module 4 — Radioiodine, Thyroid Cancer Pharmacotherapy, and Special Contexts

Chapter 30 — Thyroid Pharmacology — Module 4 — Radioiodine, Thyroid Cancer Pharmacotherapy, and Special Contexts
Tier: CC (Core Concepts)

1. Iodine-131 (I-131) is concentrated in thyroid follicular cells via the sodium-iodide symporter (NIS). Which of the following best describes the primary mechanism responsible for the therapeutic destruction of thyroid tissue following I-131 administration?

A) Gamma radiation emitted by I-131 deposits energy throughout the body, producing systemic immunosuppression that eliminates thyroid tissue indirectly.
B) Beta particles emitted by I-131 deposit their energy locally within the concentrating follicular cell, producing double-strand DNA breaks and progressive follicular destruction.
C) I-131 is converted intracellularly to a cytotoxic iodine metabolite that poisons the electron transport chain, causing mitochondrial failure and necrosis.
D) Alpha particles emitted by I-131 penetrate deeply into surrounding tissues, causing widespread radiation damage beyond the thyroid gland.
E) I-131 binds covalently to thyroid peroxidase (TPO), permanently inactivating the enzyme and preventing all further thyroid hormone synthesis.

ANSWER: B

Rationale:

This question asked you to identify the primary mechanism of I-131 therapeutic action. Option B is correct. I-131 emits beta particles with a tissue range of approximately 1-2 mm, which deposit most of their energy within the follicular cell that concentrated them. This highly localized energy deposition produces double-strand DNA breaks, leading to progressive follicular destruction over 6-12 weeks after administration. The short tissue range of beta particles is precisely what makes I-131 therapeutically precise — destruction is concentrated within NIS-expressing cells.

Option A: Option A is incorrect: gamma radiation is also emitted by I-131, but it is the beta particle component, not gamma, that drives the therapeutic effect; gamma rays pass through tissue with little local energy deposition and are used for imaging (whole-body scintigraphy), not for tissue destruction.
Option C: Option C is incorrect: I-131 does not generate a cytotoxic iodine metabolite; its therapeutic action is radiophysical, not biochemical.
Option D: Option D is incorrect: I-131 does not emit alpha particles; it is a beta-gamma emitter, and no alpha emission is involved in its mechanism of action.
Option E: Option E is incorrect: covalent inactivation of TPO is the mechanism of thionamide drugs (propylthiouracil and methimazole), not I-131; I-131 acts through ionizing radiation, not enzyme inhibition.

2. Before administering radioactive iodine (RAI) for thyroid remnant ablation in a patient with differentiated thyroid cancer (DTC), a minimum serum thyroid-stimulating hormone (TSH) level must be achieved to maximize sodium-iodide symporter (NIS) expression in residual thyroid tissue. What is the required TSH threshold?

A) TSH must be suppressed below 0.1 mIU/L to allow maximum RAI uptake through downregulation of competing thyroid tissue.
B) TSH must exceed 10 mIU/L, which is sufficient to stimulate NIS expression without causing symptomatic hypothyroidism.
C) TSH must exceed 100 mIU/L, as only very high TSH levels activate NIS transcription adequately for RAI to be effective.
D) TSH must exceed 30 mIU/L, since NIS transcription is TSH-dependent and this threshold ensures adequate RAI uptake in remnant and metastatic thyroid tissue.
E) Any detectable TSH level is sufficient, because NIS expression is constitutive in differentiated thyroid cancer cells and does not require TSH stimulation.

ANSWER: D

Rationale:

This question asked you to recall the TSH threshold required before RAI administration. Option D is correct. TSH stimulation above 30 mIU/L is the established threshold required before RAI administration to maximize NIS expression in thyroid remnant and metastatic disease. NIS transcription is TSH-dependent, meaning that without adequate TSH stimulation, NIS expression is insufficient for meaningful RAI uptake. This threshold can be achieved either by thyroid hormone withdrawal or by recombinant human thyroid-stimulating hormone (rhTSH) injection.

Option A: Option A is incorrect: TSH suppression is the goal of suppressive therapy after RAI treatment, not a pre-RAI requirement; suppressed TSH reduces rather than increases NIS expression and would impair RAI uptake.
Option B: Option B is incorrect: a TSH of 10 mIU/L is below the required threshold of 30 mIU/L and would not provide adequate NIS stimulation.
Option C: Option C is incorrect: while TSH levels after hormone withdrawal often exceed 50-100 mIU/L, the stated minimum threshold is 30 mIU/L, not 100 mIU/L; requiring 100 mIU/L is not the clinical standard.
Option E: Option E is incorrect: NIS expression is not constitutive in differentiated thyroid cancer cells; it is TSH-dependent, and inadequate TSH stimulation results in poor RAI uptake and failed ablation.

3. A patient with low-risk differentiated thyroid cancer (DTC) is scheduled for radioactive iodine (RAI) remnant ablation using recombinant human thyroid-stimulating hormone (rhTSH, thyrotropin alfa) to avoid thyroid hormone withdrawal. Which of the following correctly describes the rhTSH administration protocol?

A) Thyrotropin alfa 0.9 mg is injected intramuscularly on two consecutive days, with RAI administered on the third day; serum TSH peaks at approximately 24 hours after the final injection.
B) Thyrotropin alfa is given as a single intravenous infusion on the day before RAI, with TSH peaking 4 hours after infusion and returning to baseline by 24 hours.
C) Thyrotropin alfa 0.45 mg is injected subcutaneously weekly for four weeks to build cumulative TSH stimulation before RAI is administered on day 29.
D) Thyrotropin alfa is administered as a continuous subcutaneous infusion over 72 hours to maintain steady-state TSH elevation throughout the RAI administration and early uptake period.
E) Thyrotropin alfa 1.8 mg is given as a single intramuscular injection 48 hours before RAI; this single high dose produces equivalent TSH stimulation to the two-dose protocol.

ANSWER: A

Rationale:

This question asked you to identify the correct rhTSH administration protocol for RAI preparation. Option A is correct. The approved thyrotropin alfa (Thyrogen) protocol consists of 0.9 mg intramuscular injection on two consecutive days, with RAI administered on the third day. Serum TSH peaks at approximately 24 hours after the final injection, typically exceeding 100 mIU/L. TSH returns to baseline by approximately 72 hours. This protocol maintains euthyroidism throughout, preserving quality of life compared to thyroid hormone withdrawal, and is approved for remnant ablation in low-to-intermediate-risk DTC.

Option B: Option B is incorrect: thyrotropin alfa is administered intramuscularly, not intravenously, and the two-dose over two days protocol — not a single-dose protocol — is the approved regimen.
Option C: Option C is incorrect: there is no weekly four-week induction protocol for thyrotropin alfa; the approved protocol is two daily injections with a short time-to-peak TSH response, not a prolonged cumulative approach.
Option D: Option D is incorrect: thyrotropin alfa is not given as a continuous infusion; it is administered as discrete intramuscular injections.
Option E: Option E is incorrect: the approved protocol requires two 0.9 mg injections, not a single 1.8 mg dose; there is no approved single-injection equivalent.

4. Patients preparing for radioactive iodine (RAI) administration are instructed to follow a low-iodine diet (below 50 mcg iodine per day) for 1-2 weeks before and briefly after RAI administration. What is the pharmacological rationale for this dietary restriction?

A) Dietary iodine restriction reduces serum TSH levels, allowing higher RAI doses to be administered safely without exceeding the bone marrow radiation tolerance limit.
B) Excess dietary iodine competitively inhibits the sodium-iodide symporter (NIS) at the protein level through direct allosteric antagonism, blocking I-131 entry into thyroid cells.
C) Depleting the body's stable iodine pool reduces competition with I-131 for NIS-mediated uptake, maximizing the fraction of administered I-131 that is concentrated in thyroid remnant and metastatic tissue.
D) The low-iodine diet prevents the Wolff-Chaikoff effect, which would otherwise suppress NIS expression and reduce I-131 uptake during the first 48 hours after administration.
E) Dietary iodine restriction is required to prevent iodide-induced hyperthyroidism from occurring during the RAI preparation period in patients with residual thyroid tissue.

ANSWER: C

Rationale:

This question asked you to identify why a low-iodine diet is required before RAI. Option C is correct. The sodium-iodide symporter (NIS) concentrates both stable (non-radioactive) iodine and I-131 from the bloodstream into thyroid follicular cells. When the body has a large pool of stable iodine — from dietary intake, contrast agents, or iodine-rich medications — this stable iodine competes with I-131 for NIS-mediated uptake. By depleting stable iodine through dietary restriction for 1-2 weeks before RAI, the proportion of administered I-131 that is concentrated in residual thyroid remnant and metastatic disease is maximized, improving both ablation efficacy and the sensitivity of post-treatment whole-body scanning.

Option A: Option A is incorrect: dietary iodine restriction does not reduce TSH levels and has no relationship to bone marrow dosimetry; bone marrow tolerance is managed through dosimetric calculations of whole-body I-131 retention, not dietary preparation.
Option B: Option B is incorrect: stable iodine does not allosterically inhibit NIS at the protein level; competition is at the substrate level — both stable iodine and I-131 are substrates for the same transporter, and the one in greater abundance occupies more transport cycles.
Option D: Option D is incorrect: the Wolff-Chaikoff effect is the autoregulatory suppression of thyroid hormone synthesis by iodine excess, not an effect on NIS expression per se; and the low-iodine diet is not designed to prevent the Wolff-Chaikoff effect — it is designed to maximize competitive I-131 uptake.
Option E: Option E is incorrect: iodide-induced hyperthyroidism (Jod-Basedow phenomenon) is a concern in patients with pre-existing thyroid autonomy, but the low-iodine diet requirement before RAI is universal and its purpose is to improve I-131 uptake, not to prevent hyperthyroidism.

5. The HiLo trial compared two I-131 activities for thyroid remnant ablation in low-risk differentiated thyroid cancer (DTC) patients prepared with recombinant human TSH (rhTSH). Which of the following best describes the trial's principal finding?

A) High-activity I-131 (3.7 GBq, approximately 100 mCi) achieved significantly superior 3-year remission rates compared to low-activity I-131 (1.1 GBq, approximately 30 mCi) when both were combined with rhTSH stimulation.
B) Low-activity I-131 resulted in inferior ablation success when combined with rhTSH stimulation, confirming that high-activity I-131 is required for all patients regardless of risk category.
C) The HiLo trial demonstrated that thyroid hormone withdrawal is superior to rhTSH stimulation for achieving successful remnant ablation regardless of the I-131 activity used.
D) Neither low-activity nor high-activity I-131 achieved acceptable ablation rates when combined with rhTSH stimulation, establishing thyroid hormone withdrawal as mandatory before RAI.
E) Low-activity I-131 (1.1 GBq, approximately 30 mCi) was non-inferior to high-activity I-131 (3.7 GBq, approximately 100 mCi) for remnant ablation in low-risk DTC when both were combined with rhTSH stimulation, with substantially reduced radiation exposure.

ANSWER: E

Rationale:

This question asked you to recall the principal finding of the HiLo trial. Option E is correct. The HiLo trial demonstrated that low-activity I-131 (1.1 GBq, approximately 30 mCi) is non-inferior to high-activity I-131 (3.7 GBq, approximately 100 mCi) for thyroid remnant ablation in low-risk DTC when both groups were prepared with rhTSH stimulation. Three-year remission rates were equivalent between groups, while the low-activity arm delivered substantially reduced radiation exposure to the patient. This trial established the evidence base for using lower I-131 activities in low-risk patients, avoiding unnecessary radiation burden without sacrificing efficacy.

Option A: Option A is incorrect: this reverses the trial's finding; it was the low-activity arm, not the high-activity arm, that was found to be equivalent in efficacy, and no significant superiority of high-activity I-131 was demonstrated.
Option B: Option B is incorrect: this also reverses the conclusion; low-activity I-131 with rhTSH was not inferior — it was equivalent — to high-activity I-131.
Option C: Option C is incorrect: the HiLo trial was not a head-to-head comparison of rhTSH versus thyroid hormone withdrawal; both trial arms used rhTSH stimulation, and the variable being tested was I-131 activity (low versus high).
Option D: Option D is incorrect: both activity levels achieved acceptable ablation rates in the trial; the trial's finding supported low-activity use, not that both strategies failed.

6. A 52-year-old woman undergoes total thyroidectomy for differentiated thyroid cancer (DTC) with gross extrathyroidal extension and two confirmed pulmonary metastases. She is started on levothyroxine post-operatively. According to ATA (American Thyroid Association) risk-stratified TSH suppression guidelines, what is the appropriate TSH target during the initial post-treatment phase?

A) TSH 0.5-2.0 mIU/L, which is the standard replacement range and avoids the skeletal and cardiovascular risks of suppressive therapy.
B) TSH below 0.1 mIU/L, reflecting the high-risk classification from gross extrathyroidal extension and distant metastases, to minimize the TSH-driven trophic stimulus to residual cancer cells.
C) TSH 0.1-0.5 mIU/L, which is the ATA intermediate-risk target and represents an acceptable balance between cancer suppression and side effect avoidance.
D) TSH below 0.01 mIU/L, as the most aggressive suppression possible is required for any patient with known metastatic disease regardless of guideline-specified targets.
E) TSH does not need to be suppressed in the first year because RAI therapy is the primary treatment for pulmonary metastases and levothyroxine is given only for replacement.

ANSWER: B

Rationale:

This question asked you to apply ATA risk-stratified TSH suppression targets to a high-risk DTC patient. Option B is correct. This patient has gross extrathyroidal extension and distant (pulmonary) metastases, placing her in the ATA high-risk category. For high-risk patients during the initial post-treatment phase, the ATA guidelines specify a TSH target below 0.1 mIU/L. TSH drives expression of thyroid-specific growth factors, NIS, thyroglobulin, and thyroid peroxidase (TPO) in residual cancer cells, so its suppression reduces the proliferative stimulus and likelihood of recurrence. In high-risk patients with known disease, the benefit of aggressive suppression outweighs the long-term skeletal and cardiovascular risks.

Option A: Option A is incorrect: TSH 0.5-2.0 mIU/L is the target for low-risk patients after two years of excellent response, not for newly diagnosed high-risk disease with active distant metastases.
Option C: Option C is incorrect: TSH 0.1-0.5 mIU/L is the ATA initial target for intermediate-risk disease; this patient's gross extrathyroidal extension and distant metastases place her in the high-risk category requiring a more aggressive target below 0.1 mIU/L.
Option D: Option D is incorrect: while aggressive suppression is appropriate, there is no defined target below 0.01 mIU/L; the ATA guideline specifies below 0.1 mIU/L for high-risk patients, and attempting to drive TSH below 0.01 mIU/L is not the clinical standard and would increase toxicity without established benefit.
Option E: Option E is incorrect: TSH suppression is initiated in parallel with RAI therapy in high-risk DTC patients; levothyroxine serves both replacement and suppression functions and is not withheld pending RAI outcomes.

7. A 68-year-old postmenopausal woman with differentiated thyroid cancer (DTC) has been on suppressive levothyroxine therapy with TSH consistently below 0.1 mIU/L for 5 years. Her oncologist is now concerned about the long-term skeletal consequences of this regimen. Which of the following best describes the skeletal risk profile of prolonged TSH suppression?

A) Prolonged TSH suppression causes trabecular bone loss equally in premenopausal and postmenopausal women because thyroid hormone acts directly on osteoblasts regardless of estrogen status.
B) Prolonged TSH suppression preferentially affects cancellous (trabecular) bone of the vertebral bodies in all patients, with fracture risk primarily at the spine rather than the hip or wrist.
C) Skeletal risk from TSH suppression is negligible when TSH is maintained between 0.05 and 0.1 mIU/L because only complete TSH suppression below 0.01 mIU/L produces meaningful bone mineral density loss.
D) Prolonged TSH suppression causes dose- and duration-dependent cortical bone loss predominantly affecting postmenopausal women, who lack the estrogen counter-regulation that attenuates this effect in premenopausal women.
E) Skeletal risk from TSH suppression is caused by direct TSH receptor activation on osteoclasts rather than by subclinical thyrotoxicosis from thyroid hormone excess, and is therefore unrelated to levothyroxine dose.

ANSWER: D

Rationale:

This question asked you to identify the skeletal risk profile of prolonged TSH suppression therapy. Option D is correct. Sustained subclinical thyrotoxicosis from TSH suppression reduces bone mineral density (BMD) through increased osteoclast activity driven by thyroid hormone excess. The effect is dose- and duration-dependent. Cortical bone — which predominates at the hip, wrist, and long bone shafts — is preferentially affected. Postmenopausal women are at substantially higher risk than premenopausal women because estrogen normally attenuates osteoclast-driven bone resorption; without this counter-regulation, the thyroid hormone-driven osteoclast activation proceeds unchecked. DXA screening and consideration of antiresorptive therapy are warranted in postmenopausal women on sustained TSH suppression below 0.1 mIU/L.

Option A: Option A is incorrect: the risk is not equal between premenopausal and postmenopausal women; premenopausal estrogen significantly attenuates the bone loss, which is why postmenopausal women are the primary population requiring monitoring and intervention.
Option B: Option B is incorrect: while vertebral trabecular bone is affected by many osteoporotic processes, the predominant skeletal effect of TSH suppression is on cortical bone, not trabecular bone; cortical sites including the hip are the main concern.
Option C: Option C is incorrect: no defined lower threshold of TSH suppression between 0.05 and 0.1 mIU/L has been established as safe for bone; BMD loss is a continuous risk that increases with degree and duration of suppression below the normal range.
Option E: Option E is incorrect: the skeletal harm is caused by subclinical thyrotoxicosis from excess thyroid hormone driving osteoclast activity, not by direct TSH receptor signaling on osteoclasts; the mechanism is thyroid hormone-mediated, not TSH-receptor-mediated.

8. A 65-year-old man with differentiated thyroid cancer (DTC) has been maintained on suppressive levothyroxine therapy for 8 years, with TSH consistently below 0.1 mIU/L. He presents for annual follow-up. Which cardiovascular complication of long-term TSH suppression should be actively screened for in this patient?

A) Atrial fibrillation (AF), which occurs at two-to-threefold increased risk in older patients on sustained suppressive TSH therapy due to the chronotropic and electrophysiological effects of subclinical thyrotoxicosis.
B) Hypertrophic obstructive cardiomyopathy (HOCM), which develops in patients on long-term supraphysiological levothyroxine due to TSH receptor activation in cardiac myocytes causing asymmetric septal hypertrophy.
C) Constrictive pericarditis, which results from chronic subclinical hypothyroidism caused by overtreatment with levothyroxine and accumulation of pericardial mucopolysaccharides.
D) Complete heart block requiring pacemaker implantation, as prolonged supraphysiological thyroid hormone exposure damages the atrioventricular (AV) node conduction system irreversibly.
E) Pulmonary arterial hypertension, which is the primary cardiovascular consequence of chronic TSH suppression due to thyroid hormone-driven pulmonary vascular remodeling.

ANSWER: A

Rationale:

This question asked you to identify the primary cardiovascular risk of prolonged TSH suppression in an older patient. Option A is correct. Atrial fibrillation (AF) is the cardinal cardiovascular risk of sustained TSH suppression, occurring at two-to-threefold increased risk in patients over 60. Subclinical thyrotoxicosis from supraphysiological levothyroxine doses accelerates heart rate, increases left ventricular mass, shortens the PR interval, and creates the electrophysiological substrate for AF. Patients over 60 on suppressive therapy should be monitored for AF on a scheduled basis, and cardiovascular risk factors should be aggressively managed. Early de-escalation of TSH suppression targets when oncologically appropriate is the primary prevention strategy.

Option B: Option B is incorrect: hypertrophic obstructive cardiomyopathy is not a recognized consequence of TSH suppression; while subclinical thyrotoxicosis does increase left ventricular mass, this is not the same as HOCM, which is a genetic condition with asymmetric septal hypertrophy caused by sarcomere protein mutations.
Option C: Option C is incorrect: constrictive pericarditis is a manifestation of hypothyroidism (myxedema pericardial effusion), not of subclinical thyrotoxicosis; patients on suppressive therapy are in a state of mild thyroid hormone excess, not deficiency.
Option D: Option D is incorrect: complete heart block is not a recognized complication of prolonged TSH suppression; thyrotoxicosis tends to accelerate conduction rather than impair it.
Option E: Option E is incorrect: pulmonary arterial hypertension is not an established cardiovascular consequence of TSH suppression; it is associated with various connective tissue and cardiopulmonary diseases, not with subclinical thyrotoxicosis from DTC management.

9. A patient with papillary thyroid cancer and pulmonary metastases is being evaluated for further systemic therapy. Her oncologist states that she has "RAI-refractory differentiated thyroid cancer." Which of the following best defines this clinical classification?

A) RAI-refractory DTC is defined solely by a total cumulative I-131 activity above 400 mCi administered over the patient's lifetime, regardless of tumor response or imaging findings.
B) RAI-refractory DTC is defined by failure of the first RAI treatment to achieve complete ablation of the thyroid remnant, requiring transition to targeted therapy after a single unsuccessful RAI course.
C) RAI-refractory DTC is defined by absent RAI uptake in metastatic lesions, progression of structural disease during or after RAI therapy, or a total cumulative RAI activity above 600 mCi without complete response.
D) RAI-refractory DTC is defined exclusively by loss of NIS expression confirmed by molecular profiling of a tumor biopsy specimen showing absent NIS mRNA.
E) RAI-refractory DTC applies only to patients with anaplastic thyroid cancer, as papillary and follicular tumors retain NIS expression throughout their clinical course and never become truly RAI-refractory.

ANSWER: C

Rationale:

This question asked you to identify the clinical definition of RAI-refractory differentiated thyroid cancer. Option C is correct. RAI-refractory DTC is a clinical classification defined by any of the following: absent RAI uptake in metastatic lesions on whole-body scintigraphy; structural disease progression during or after RAI therapy despite documented uptake; or a total cumulative RAI activity above 600 mCi without complete response. Approximately 5-15% of DTC patients develop RAI-refractory disease, and this subset accounts for the majority of thyroid cancer mortality. The underlying mechanism typically involves dedifferentiation with loss of NIS expression, driven by activating mutations in the MAPK pathway including BRAF V600E and RAS mutations.

Option A: Option A is incorrect: the threshold for cumulative activity is 600 mCi, not 400 mCi, and cumulative activity alone is not sufficient to define refractoriness — absent uptake or structural progression are equally defining criteria.
Option B: Option B is incorrect: failure of a single RAI course to achieve complete remnant ablation is not the definition of RAI refractoriness; multiple RAI treatments may be appropriate, and the classification requires evidence of absent uptake or structural progression, not simply incomplete first-course ablation.
Option D: Option D is incorrect: RAI refractoriness is a clinical and imaging classification, not a molecular diagnosis requiring NIS mRNA quantification; molecular profiling may support the classification but is not its definition.
Option E: Option E is incorrect: anaplastic thyroid cancer is not classified as RAI-refractory DTC; anaplastic thyroid cancer arises from undifferentiated cells and never concentrates RAI to begin with, making it a separate histological entity; RAI-refractory DTC refers specifically to formerly iodine-avid differentiated tumors (papillary and follicular) that lose this property.

10. Sorafenib is an FDA-approved multi-kinase inhibitor for radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC). Its approval was based on a phase 3 randomized controlled trial. Which of the following correctly describes sorafenib's mechanism of action and the key finding of its registration trial?

A) Sorafenib selectively inhibits the RET kinase and was approved based on the SELECT trial, which demonstrated a median progression-free survival (PFS) of 18.3 months versus 3.6 months for placebo.
B) Sorafenib inhibits VEGFR and PDGFR but not RAF kinases; its approval was based on a phase 2 single-arm trial showing a 40% objective response rate without a randomized placebo comparison.
C) Sorafenib was the first approved agent for RAI-refractory DTC and acts primarily by inhibiting TSH receptor signaling in dedifferentiated thyroid cancer cells to restore RAI uptake.
D) Sorafenib selectively inhibits BRAF V600E and was approved specifically for anaplastic thyroid cancer based on the ROAR (Rare Oncology Agnostic Research) basket trial.
E) Sorafenib targets VEGFR, PDGFR, and RAF kinases and was approved based on the DECISION trial, which demonstrated improved median progression-free survival from 5.8 months with placebo to 10.8 months with sorafenib.

ANSWER: E

Rationale:

This question asked you to identify sorafenib's mechanism and the key finding of its registration trial in RAI-refractory DTC. Option E is correct. Sorafenib is a multi-kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF kinases. It was approved for RAI-refractory locally advanced or metastatic DTC based on the DECISION trial (2013), a phase 3 randomized placebo-controlled study that demonstrated improved median progression-free survival from 5.8 months with placebo to 10.8 months with sorafenib.

Option A: Option A is incorrect: the SELECT trial was the registration trial for lenvatinib, not sorafenib; lenvatinib achieved median PFS of 18.3 months versus 3.6 months with placebo; sorafenib's trial was the DECISION trial with the 5.8 to 10.8 month PFS result.
Option B: Option B is incorrect: sorafenib does target RAF kinases in addition to VEGFR and PDGFR; the DECISION trial was a randomized phase 3 study versus placebo, not a single-arm phase 2 study.
Option C: Option C is incorrect: sorafenib does not inhibit TSH receptor signaling and does not restore RAI uptake; it targets angiogenic and proliferative kinase pathways; restoring RAI sensitivity (redifferentiation therapy) is a separate investigational approach using BRAF/MEK inhibitors.
Option D: Option D is incorrect: sorafenib does not selectively inhibit BRAF V600E; it is a broad multi-kinase inhibitor; the BRAF V600E-targeted combination of dabrafenib plus trametinib, approved based on the ROAR basket trial, is the regimen used for anaplastic thyroid cancer.

11. Lenvatinib is a second FDA-approved multi-kinase inhibitor for RAI-refractory differentiated thyroid cancer (DTC). Compared to sorafenib, lenvatinib demonstrated more striking efficacy in its registration trial. Which of the following correctly describes the key outcome data from lenvatinib's registration trial?

A) The SELECT trial demonstrated that lenvatinib improved overall survival compared to placebo, with a median overall survival benefit of 14 months and a 30% objective response rate.
B) The SELECT trial demonstrated that lenvatinib achieved a median progression-free survival (PFS) of 18.3 months versus 3.6 months with placebo, with a 65% objective response rate — substantially higher than sorafenib's response rate.
C) The SELECT trial was a head-to-head comparison of lenvatinib versus sorafenib that demonstrated lenvatinib's superiority with a hazard ratio of 0.52 for progression-free survival.
D) The SELECT trial demonstrated lenvatinib's efficacy specifically in medullary thyroid cancer (MTC) based on its potent RET inhibition, achieving a 65% calcitonin normalization rate.
E) The SELECT trial showed lenvatinib improved median PFS from 18.3 months with placebo to 36.6 months with lenvatinib in a heavily pretreated RAI-refractory DTC population with prior sorafenib exposure.

ANSWER: B

Rationale:

This question asked you to recall the key efficacy data from lenvatinib's SELECT trial in RAI-refractory DTC. Option B is correct. The SELECT trial (2015) was a phase 3 randomized placebo-controlled study that demonstrated lenvatinib achieved a median progression-free survival of 18.3 months versus 3.6 months with placebo in RAI-refractory DTC. The objective response rate of 65% was substantially higher than that seen with sorafenib in the DECISION trial. Lenvatinib targets VEGFR, PDGFR, and RAF kinases, with additional inhibitory activity against FGFR (fibroblast growth factor receptor) and RET.

Option A: Option A is incorrect: the SELECT trial's primary endpoint was progression-free survival, not overall survival; overall survival benefit was not demonstrated as a statistically significant endpoint; and the 30% response rate figure belongs to sorafenib's DECISION trial results, not lenvatinib's.
Option C: Option C is incorrect: the SELECT trial was not a head-to-head comparison of lenvatinib versus sorafenib; it was a comparison of lenvatinib versus placebo; no direct head-to-head randomized trial of these two agents in DTC has been completed.
Option D: Option D is incorrect: the SELECT trial enrolled patients with RAI-refractory differentiated thyroid cancer, not medullary thyroid cancer; lenvatinib's primary indication in MTC has less supporting data than in DTC, and calcitonin normalization is a medullary thyroid cancer endpoint, not a DTC endpoint.
Option E: Option E is incorrect: this reverses the PFS numbers; the placebo arm had median PFS of 3.6 months and lenvatinib had 18.3 months — not the other way around; and the SELECT trial did not require prior sorafenib exposure.

12. A 45-year-old man is diagnosed with medullary thyroid cancer (MTC) after presenting with a neck mass and elevated serum calcitonin. Genetic testing reveals a germline RET (rearranged during transfection proto-oncogene) mutation. Which of the following best describes the fundamental pharmacological and biological characteristics of MTC that distinguish it from differentiated thyroid cancer?

A) MTC arises from calcitonin-secreting parafollicular C-cells, does not concentrate radioactive iodine because C-cells lack NIS expression, and is driven by activating RET proto-oncogene mutations in heritable cases.
B) MTC arises from follicular cells, concentrates radioactive iodine via NIS, and is therefore amenable to I-131 therapy; RET mutations drive dedifferentiation and RAI refractoriness in advanced cases.
C) MTC arises from parafollicular C-cells but retains partial NIS expression, making low-dose RAI (30 mCi) an effective adjunct to surgery in patients without distant metastases.
D) MTC is caused exclusively by somatic RET mutations in sporadic cases and never by germline mutations; hereditary MTC with germline RET mutations constitutes a separate disease entity classified under neuroendocrine tumor syndromes.
E) MTC arises from follicular cells and secretes calcitonin only in advanced dedifferentiated disease; early-stage MTC secretes thyroglobulin and is monitored with serum thyroglobulin levels, not calcitonin.

ANSWER: A

Rationale:

This question asked you to identify the key biological characteristics of medullary thyroid cancer. Option A is correct. MTC arises from parafollicular C-cells, which are neuroendocrine cells derived from neural crest and are responsible for calcitonin secretion. C-cells do not express the sodium-iodide symporter (NIS), which means MTC does not concentrate radioactive iodine and I-131 therapy is not effective. In heritable cases — approximately 25% of all MTC — germline mutations in the RET proto-oncogene drive tumorigenesis; the specific RET codon mutation correlates with phenotypic aggressiveness and guides prophylactic thyroidectomy timing in MEN2 (multiple endocrine neoplasia type 2) kindreds. Calcitonin and carcinoembryonic antigen (CEA) are the serum biomarkers for monitoring MTC treatment response.

Option B: Option B is incorrect: MTC arises from C-cells, not follicular cells, and C-cells lack NIS expression; I-131 therapy is not effective for MTC under any circumstances, not just in advanced cases.
Option C: Option C is incorrect: MTC does not retain partial NIS expression; it has no NIS expression because C-cells are not of follicular epithelial origin; RAI is never used in the management of MTC.
Option D: Option D is incorrect: while the majority of MTC cases are sporadic with somatic RET mutations, heritable MTC with germline RET mutations is well established as part of MEN2A and MEN2B syndromes and is not classified as a separate disease entity from MTC.
Option E: Option E is incorrect: calcitonin is the characteristic secretory product of C-cells at all stages of MTC, not only advanced disease; thyroglobulin is produced by follicular cells and is not a marker for MTC.

13. Two multi-kinase inhibitors are FDA-approved for progressive medullary thyroid cancer (MTC): vandetanib and cabozantinib. Both target RET kinase and VEGFR. However, each agent has an additional kinase target that distinguishes it from the other. Which of the following correctly pairs each agent with its distinguishing additional target?

A) Vandetanib additionally inhibits MET (hepatocyte growth factor receptor), which is relevant to its activity in RET wild-type MTC; cabozantinib additionally inhibits EGFR.
B) Both vandetanib and cabozantinib share identical kinase profiles, targeting only RET, VEGFR, and PDGFR; the two agents are pharmacologically interchangeable in clinical practice.
C) Vandetanib additionally inhibits ALK (anaplastic lymphoma kinase), making it effective in RET-fusion-positive thyroid cancers; cabozantinib additionally inhibits FGFR.
D) Vandetanib additionally inhibits EGFR (epidermal growth factor receptor); cabozantinib additionally inhibits MET (hepatocyte growth factor receptor), which is relevant to its efficacy in RET wild-type MTC.
E) Vandetanib additionally inhibits BRAF kinase, accounting for its efficacy in BRAF V600E-mutant MTC; cabozantinib additionally inhibits MEK kinase in the MAP kinase pathway.

ANSWER: D

Rationale:

This question asked you to distinguish the additional kinase targets of vandetanib and cabozantinib beyond their shared RET/VEGFR inhibition. Option D is correct. Vandetanib additionally inhibits EGFR (epidermal growth factor receptor) beyond its RET and VEGFR targets. Cabozantinib additionally inhibits MET (hepatocyte growth factor receptor) kinase; MET pathway activation is a mechanism of resistance and disease progression in RET wild-type MTC, making cabozantinib's MET inhibition clinically relevant in this population. Both agents are approved for progressive MTC based on phase 3 data (vandetanib: ZETA trial, 2011; cabozantinib: EXAM trial, 2012), and their selection may be guided by mutational status and toxicity profile.

Option A: Option A is incorrect: this reverses the agents — MET inhibition belongs to cabozantinib, not vandetanib; EGFR inhibition belongs to vandetanib, not cabozantinib.
Option B: Option B is incorrect: vandetanib and cabozantinib have distinct kinase profiles beyond their shared targets; they are not pharmacologically interchangeable, and their additional targets have clinical implications for specific patient populations.
Option C: Option C is incorrect: neither vandetanib nor cabozantinib inhibits ALK; ALK inhibition is relevant to lung adenocarcinoma and ALK-fusion-positive tumors but not to the approved MTC indication; FGFR inhibition is an additional target of lenvatinib, not cabozantinib.
Option E: Option E is incorrect: neither vandetanib nor cabozantinib selectively inhibits BRAF V600E or MEK; BRAF inhibition combined with MEK inhibition (dabrafenib plus trametinib) is the approved approach for BRAF V600E-mutant anaplastic thyroid cancer, not MTC.

14. A 61-year-old woman presents with rapidly enlarging neck mass, stridor, and dysphagia. Biopsy reveals anaplastic thyroid cancer (ATC). Molecular profiling identifies a BRAF V600E mutation. Which FDA-approved targeted therapy combination is indicated for her disease, and what was the basis for its approval?

A) Sorafenib plus lenvatinib combination therapy, approved based on the SELECT trial extension cohort that included anaplastic thyroid cancer patients with BRAF V600E mutations.
B) Selpercatinib monotherapy, approved for BRAF V600E-mutant anaplastic thyroid cancer based on the LIBRETTO-001 trial demonstrating a 70% response rate in this histology.
C) Dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor), approved in 2022 for locally advanced or metastatic BRAF V600E-mutant anaplastic thyroid cancer based on the ROAR basket trial demonstrating responses in approximately 69% of patients.
D) Vandetanib plus cabozantinib combination, approved for anaplastic thyroid cancer with BRAF V600E mutation based on additive RET plus BRAF pathway inhibition producing synergistic tumor regression.
E) Vemurafenib monotherapy (selective BRAF V600E inhibitor), approved specifically for ATC after the BRAF-ATC trial demonstrated durable complete responses in 40% of patients with BRAF V600E-mutant tumors.

ANSWER: C

Rationale:

This question asked you to identify the approved targeted therapy for BRAF V600E-mutant anaplastic thyroid cancer and its trial basis. Option C is correct. The combination of dabrafenib, a BRAF inhibitor, plus trametinib, a MEK (mitogen-activated protein kinase kinase) inhibitor, received FDA approval in 2022 for locally advanced or metastatic BRAF V600E-mutant anaplastic thyroid cancer. The approval was based on the ROAR (Rare Oncology Agnostic Research) basket trial, which demonstrated responses in approximately 69% of ATC patients with BRAF V600E mutations — a remarkable result in a malignancy with historically dismal prognosis and median survival measured in weeks to months. Dual BRAF plus MEK inhibition is used because BRAF inhibitor monotherapy leads to rapid resistance through MEK-dependent feedback reactivation of the MAPK pathway.

Option A: Option A is incorrect: sorafenib and lenvatinib are not approved in combination; each is approved as monotherapy for RAI-refractory DTC, not for anaplastic thyroid cancer.
Option B: Option B is incorrect: selpercatinib targets RET fusions and RET mutations, not BRAF V600E; it is approved for RET-altered thyroid cancers including medullary thyroid cancer and RET-fusion-positive DTC, not for BRAF V600E-mutant ATC.
Option D: Option D is incorrect: vandetanib and cabozantinib are approved for MTC, not for ATC; there is no approved combination of these two agents for any thyroid cancer indication.
Option E: Option E is incorrect: vemurafenib is a selective BRAF V600E inhibitor used in melanoma but is not specifically FDA-approved for anaplastic thyroid cancer; the approved BRAF-directed regimen for ATC uses dabrafenib plus trametinib, not vemurafenib monotherapy.

15. A cardiologist initiates amiodarone for a patient with refractory ventricular tachycardia. Before starting therapy, the cardiologist counsels the patient about thyroid effects. Which of the following best describes amiodarone's iodine burden and the pharmacokinetic properties that make its thyroid effects long-lasting?

A) Amiodarone contains 3% iodine by weight and has a short elimination half-life of 4-8 hours, making its thyroid effects predictably reversible within 48 hours of drug discontinuation.
B) Amiodarone contains 15% iodine by weight and has a moderate volume of distribution of 5 L/kg; its thyroid effects resolve within 2-4 weeks of discontinuation in most patients.
C) Amiodarone contains 37% iodine by weight but has a volume of distribution of only 2 L/kg, limiting tissue accumulation; thyroid effects persist for up to 4 weeks after discontinuation due to slow renal iodine clearance.
D) Amiodarone contains 10% iodine by weight and accumulates preferentially in thyroid tissue exclusively; its elimination half-life of 7-10 days results in thyroid effects persisting for approximately 3 weeks after discontinuation.
E) Amiodarone contains 37% iodine by weight, has a volume of distribution of approximately 60 L/kg and an elimination half-life of 40-55 days, and releases approximately 6 mg of free iodide daily from a standard 200 mg tablet — far exceeding the recommended daily iodine allowance of 150 mcg.

ANSWER: E

Rationale:

This question asked you to recall the iodine burden and pharmacokinetic properties that account for amiodarone's prolonged thyroid effects. Option E is correct. Amiodarone is a benzofuran iodine-rich antiarrhythmic containing 37% iodine by weight. A standard 200 mg tablet releases approximately 6 mg of free inorganic iodide daily — far exceeding the recommended daily iodine allowance of 150 mcg. Its pharmacokinetic profile is extraordinary: a volume of distribution of approximately 60 L/kg reflects extensive accumulation in adipose, hepatic, pulmonary, and thyroid tissue, and its elimination half-life of 40-55 days means that thyroid effects persist for months after drug discontinuation. These pharmacokinetic features are directly responsible for the complexity and persistence of amiodarone-induced thyroid disease.

Option A: Option A is incorrect: amiodarone contains 37%, not 3%, iodine by weight, and its half-life is 40-55 days, not 4-8 hours; the claim that effects reverse within 48 hours is incorrect.
Option B: Option B is incorrect: 15% iodine content and a 5 L/kg volume of distribution are both substantially lower than amiodarone's actual values; the 2-4 week resolution of effects is also inconsistent with the 40-55 day half-life and months-long persistence of thyroid effects after discontinuation.
Option C: Option C is incorrect: amiodarone's volume of distribution is approximately 60 L/kg, not 2 L/kg; extensive tissue distribution — not limited distribution — is what accounts for the long half-life and persistent thyroid effects.
Option D: Option D is incorrect: amiodarone contains 37%, not 10%, iodine by weight; its elimination half-life is 40-55 days, not 7-10 days; and its accumulation is not limited to thyroid tissue — it distributes extensively into adipose, hepatic, and pulmonary tissue as well.

16. A 58-year-old man on chronic amiodarone therapy for atrial fibrillation develops symptomatic hyperthyroidism. Thyroid ultrasound with color Doppler shows increased vascularity; TSH receptor antibodies (TRAb) are negative. He has a history of longstanding multinodular goiter. Which type of amiodarone-induced thyrotoxicosis (AIT) does this presentation most likely represent, and what is its pathophysiology?

A) Type 2 AIT — a destructive thyroiditis caused by the direct cytotoxic effects of amiodarone on structurally normal thyroid follicular cells, releasing preformed hormone without new synthesis; increased Doppler vascularity confirms the inflammatory process.
B) Type 1 AIT — iodine-induced Jod-Basedow (excess-iodine-driven hypersecretion) thyrotoxicosis occurring in a patient with pre-existing thyroid autonomy from his multinodular goiter; iodine excess provides substrate driving unregulated thyroid hormone synthesis in an already-autonomous gland.
C) Mixed AIT — both types are always present simultaneously in patients with multinodular goiter because pre-existing nodular autonomy creates an inflammatory substrate that amplifies the direct cytotoxic effect.
D) Type 2 AIT — the negative TRAb result confirms that no Graves disease autoimmunity is present, and without autoimmunity, amiodarone thyrotoxicosis is always destructive thyroiditis rather than iodine-driven synthesis.
E) Type 1 AIT cannot occur in a patient with pre-existing multinodular goiter because autonomous nodules suppress TSH, protecting the gland against the Wolff-Chaikoff escape mechanism that is required for type 1 disease.

ANSWER: B

Rationale:

This question asked you to identify the type of AIT and its mechanism based on clinical features. Option B is correct. Type 1 AIT is iodine-induced Jod-Basedow thyrotoxicosis occurring specifically in patients with pre-existing thyroid autonomy — either unrecognized Graves disease or, as in this case, toxic multinodular goiter (TMNG). The iodine excess from amiodarone provides unregulated substrate to autonomous thyroid tissue that is already driving hormone synthesis independent of TSH. The increased vascularity on color Doppler reflects active ongoing synthesis and distinguishes type 1 from type 2. Treatment with methimazole (MMI) 40-60 mg/day is used, often supplemented with potassium perchlorate to reduce intrathyroidal iodine load.

Option A: Option A is incorrect: type 2 AIT is a destructive thyroiditis that occurs on a structurally normal (or previously normal) gland; the finding of increased vascularity on Doppler is characteristic of type 1 (active synthesis), not type 2 — type 2 shows absent or markedly reduced vascularity consistent with avascular thyroiditis.
Option C: Option C is incorrect: while mixed forms with features of both types do exist clinically, the presentation here with increased Doppler vascularity and a known pre-existing multinodular goiter is most consistent with type 1 AIT, not a mandatory mixed form; mixed AIT is not universally assumed in patients with pre-existing gland pathology.
Option D: Option D is incorrect: TRAb negativity rules out Graves disease autoimmunity but does not diagnose type 2 AIT; type 1 AIT does not require TRAb positivity — it requires pre-existing thyroid autonomy (nodular goiter is sufficient), and increased vascularity further confirms ongoing active synthesis consistent with type 1.
Option E: Option E is incorrect: autonomous nodules in TMNG suppress TSH but do not protect against iodine-induced excess substrate driving type 1 AIT; in fact, pre-existing autonomy is the prerequisite for type 1 AIT, not a protective factor against it.

17. A 67-year-old woman on amiodarone for ventricular arrhythmia develops symptomatic thyrotoxicosis. Thyroid ultrasound with color Doppler shows absent vascularity. She has no prior history of thyroid disease and her gland was structurally normal on a scan performed 2 years ago. Serum interleukin-6 (IL-6) is markedly elevated. What is the most appropriate pharmacological treatment for her condition?

A) Oral prednisone 40-60 mg/day, tapered over approximately 3 months, to suppress the inflammatory destructive process responsible for excess thyroid hormone release in type 2 AIT.
B) Methimazole 40-60 mg/day, the preferred antithyroid agent for type 2 AIT because it directly blocks thyroid hormone synthesis and is more effective than glucocorticoids in the destructive thyroiditis setting.
C) Propylthiouracil (PTU) 300-400 mg/day plus potassium perchlorate 200 mg four times daily to block both iodide organification and iodide transport, reducing intrathyroidal iodine load in the destructive phase.
D) Radioactive iodine (RAI) therapy at 29.6 MBq (0.8 mCi) to ablate the residual thyroid tissue responsible for hormone release, eliminating the source of excess thyroid hormone.
E) Beta-blockade with propranolol for symptomatic control only, as type 2 AIT is self-limiting and resolves without specific pharmacological intervention in all cases within 4-6 weeks.

ANSWER: A

Rationale:

This question asked you to identify the correct treatment for type 2 amiodarone-induced thyrotoxicosis. Option A is correct. Type 2 AIT is a destructive thyroiditis caused by the direct cytotoxic effects of amiodarone and its active metabolite desethylamiodarone on thyroid follicular cells. This releases preformed thyroid hormone without new synthesis. Because there is no ongoing new synthesis in type 2 AIT, antithyroid drugs that block synthesis (methimazole, PTU) are ineffective. The appropriate treatment is oral prednisone 40-60 mg/day, tapered over approximately 3 months, to suppress the inflammatory destructive process. The clinical findings in this case — absent Doppler vascularity (avascular destructive thyroiditis), normal prior gland structure, and markedly elevated IL-6 reflecting the inflammatory process — all confirm type 2 AIT.

Option B: Option B is incorrect: methimazole blocks thyroid hormone synthesis by inhibiting thyroid peroxidase, which has no effect on type 2 AIT where thyrotoxicosis results from release of preformed hormone from a destructed gland — synthesis is not the driver of hormone excess in type 2; methimazole is the treatment of type 1 AIT.
Option C: Option C is incorrect: PTU and potassium perchlorate are used in type 1 AIT to block synthesis and reduce intrathyroidal iodine load; they have no efficacy in type 2 AIT because the problem is destructive release, not synthesis.
Option D: Option D is incorrect: RAI is ineffective in amiodarone-induced thyrotoxicosis of either type because amiodarone iodine loading suppresses RAI uptake; the iodine-saturated gland will not concentrate additional I-131 meaningfully.
Option E: Option E is incorrect: while beta-blockade provides symptomatic control, type 2 AIT is not reliably self-limiting within 4-6 weeks in all cases; glucocorticoid therapy is the standard pharmacological treatment, not watchful waiting with beta-blockade only.

18. Two patients on chronic amiodarone therapy both develop thyrotoxicosis. To guide treatment decisions, the clinician orders thyroid ultrasound with color Doppler for each patient. Which of the following correctly describes the expected Doppler findings that distinguish type 1 from type 2 amiodarone-induced thyrotoxicosis (AIT), and explains why each pattern is seen?

A) Type 1 AIT produces absent vascularity on Doppler because iodine loading suppresses thyroid blood flow; type 2 AIT produces markedly increased vascularity because inflammatory cytokines increase glandular perfusion.
B) Both type 1 and type 2 AIT consistently produce absent vascularity on color Doppler because amiodarone's direct vasoconstrictor effect on thyroid vessels suppresses blood flow regardless of disease mechanism.
C) Color Doppler is not useful in distinguishing AIT types because both type 1 and type 2 thyrotoxicosis produce identical hyperemic patterns reflecting increased metabolic activity; the distinction requires radioiodine uptake scanning.
D) Type 1 AIT produces increased or normal vascularity on Doppler, reflecting active ongoing thyroid hormone synthesis in an autonomous gland; type 2 AIT produces absent or markedly reduced vascularity, reflecting avascular destructive thyroiditis without active synthesis.
E) Type 1 AIT produces hypervascularity identical to Graves disease because both involve TSH receptor antibody stimulation; type 2 AIT produces absent vascularity because the TSH receptor is not stimulated in destructive thyroiditis.

ANSWER: D

Rationale:

This question asked you to identify the color Doppler findings distinguishing AIT type 1 from type 2. Option D is correct. Thyroid ultrasound with color Doppler is the most useful non-invasive discriminator between AIT types. Type 1 AIT, in which iodine excess drives autonomous thyroid hormone synthesis in a gland with pre-existing autonomy, shows increased or normal vascularity on color Doppler — the hypervascularity reflects active, ongoing synthetic activity and blood flow to a functionally active gland. Type 2 AIT, a destructive thyroiditis caused by the direct cytotoxic effects of amiodarone on follicular cells, produces absent or markedly reduced vascularity — the gland is not synthetically active but rather releasing preformed hormone from damaged cells; the avascular pattern is consistent with thyroiditis of any destructive etiology. This Doppler distinction directly guides the treatment choice: vascularity present favors methimazole for type 1; avascularity favors prednisone for type 2.

Option A: Option A is incorrect: this reverses the Doppler findings; type 1 (active synthesis) shows increased vascularity, and type 2 (destructive) shows reduced or absent vascularity — not the other way around.
Option B: Option B is incorrect: amiodarone does not cause uniform avascular suppression in both types; the Doppler pattern differs by mechanism and is clinically useful precisely because it is not the same in both conditions.
Option C: Option C is incorrect: color Doppler is the recommended non-invasive tool for AIT type differentiation and does produce distinguishably different patterns between types 1 and 2; it is more useful than radioiodine uptake scanning in this context because amiodarone iodine loading suppresses RAI uptake in both types, making uptake scanning non-discriminatory.
Option E: Option E is incorrect: type 1 AIT is not mediated by TSH receptor antibodies; it is driven by iodine-substrate excess in an autonomously functioning gland, not by TRAb stimulation; hypervascularity in type 1 reflects autonomous synthesis, not Graves-type TRAb-driven stimulation.

19. A 28-year-old woman at 10 weeks gestation presents with nausea, vomiting, palpitations, and a serum TSH of 0.05 mIU/L with mildly elevated free T4. She has no goiter, negative TSH receptor antibodies (TRAb), and no prior thyroid history. What is the most likely diagnosis, and what is the appropriate management?

A) True Graves disease in pregnancy — initiate propylthiouracil (PTU) immediately at 100-200 mg three times daily because any TSH below 0.1 mIU/L in pregnancy represents pathological hyperthyroidism requiring antithyroid treatment.
B) Subclinical hypothyroidism — the TSH of 0.05 mIU/L indicates paradoxical pituitary suppression from hypothyroid-mediated feedback, and levothyroxine supplementation should be initiated promptly.
C) Gestational transient thyrotoxicosis (GTT) caused by hCG (human chorionic gonadotropin)-driven TSH suppression, which is physiological in the first trimester, requires no antithyroid drug treatment, and resolves spontaneously by 14-20 weeks as hCG declines.
D) Hyperemesis gravidarum with secondary permanent hypothyroidism — the TSH suppression reflects pituitary damage from severe vomiting-induced electrolyte imbalances and requires long-term thyroid hormone replacement.
E) Toxic multinodular goiter precipitated by pregnancy — the hCG-driven TSH suppression has unmasked pre-existing autonomous nodules requiring immediate methimazole therapy to prevent fetal thyrotoxicosis.

ANSWER: C

Rationale:

This question asked you to distinguish gestational transient thyrotoxicosis from true Graves disease in the first trimester. Option C is correct. Gestational transient thyrotoxicosis (GTT) is caused by hCG-driven TSH suppression. Human chorionic gonadotropin (hCG) shares structural homology with TSH and binds weakly to the TSH receptor, producing TSH suppression in up to 15% of normal pregnancies in the first trimester. The result is mild TSH suppression with mildly elevated free T4 that does not represent true hyperthyroidism requiring antithyroid treatment. The diagnosis is supported by first-trimester timing, absence of goiter, negative TRAb, and no prior thyroid disease. GTT resolves spontaneously by 14-20 weeks as hCG declines. Antithyroid drugs are not indicated and would impose fetal risk without benefit. Management of associated hyperemesis is antiemetic support and hydration.

Option A: Option A is incorrect: TSH below 0.1 mIU/L in the first trimester does not automatically indicate pathological hyperthyroidism; first-trimester TSH reference ranges are lower than non-pregnancy ranges, and GTT is a physiological, self-resolving condition that does not require antithyroid therapy; PTU initiation would be inappropriate.
Option B: Option B is incorrect: TSH of 0.05 mIU/L indicates suppression, not elevation; hypothyroidism produces elevated TSH, not suppressed TSH; and levothyroxine would be contraindicated in a patient with suppressed TSH.
Option D: Option D is incorrect: GTT is not permanent hypothyroidism; the TSH is suppressed (not elevated) consistent with hyperthyroid-range biochemistry, not hypothyroidism; pituitary damage from vomiting is not a recognized consequence of hyperemesis gravidarum.
Option E: Option E is incorrect: toxic multinodular goiter requires a goiter with autonomous nodules on imaging, which is absent here; GTT occurs in structurally normal glands and is attributable to hCG stimulation, not to underlying nodular autonomy.

20. A 31-year-old woman with known Graves disease becomes pregnant. Her endocrinologist switches her to propylthiouracil (PTU) for the first trimester and plans her ongoing management. She asks about "block-and-replace" therapy, which a friend described as combining an antithyroid drug with levothyroxine. Why is the block-and-replace strategy contraindicated in pregnancy?

A) Block-and-replace is contraindicated in pregnancy because propylthiouracil and levothyroxine interact pharmacokinetically, with levothyroxine accelerating PTU hepatic metabolism and producing subtherapeutic antithyroid drug levels.
B) Block-and-replace is contraindicated because the levothyroxine component of the combination crosses the placenta in large amounts, causing fetal hyperthyroidism from exogenous thyroid hormone supplementation.
C) Block-and-replace is contraindicated because the combination produces rebound hypothyroidism in the mother when levothyroxine is stopped at delivery, causing severe postpartum thyroid storm in women with Graves disease.
D) Block-and-replace is not contraindicated in pregnancy; it is in fact the preferred strategy because it allows stable maternal free T4 levels while avoiding the need for frequent dose adjustments.
E) Block-and-replace is contraindicated in pregnancy because the levothyroxine component does not cross the placenta in meaningful amounts, meaning the fetus receives the full antithyroid drug effect without the thyroid hormone replacement — exposing the fetus to higher cumulative thionamide doses and greater risk of fetal hypothyroidism and goiter.

ANSWER: E

Rationale:

This question asked you to explain why the block-and-replace strategy is specifically contraindicated in pregnancy. Option E is correct. The block-and-replace strategy uses a full blocking dose of antithyroid drug (PTU or methimazole) alongside supplemental levothyroxine to maintain maternal euthyroidism. In non-pregnant adults, this produces stable thyroid function and avoids the need for frequent dose adjustments. However, in pregnancy, this strategy is specifically contraindicated because thionamides (both PTU and methimazole) cross the placenta readily, while levothyroxine crosses the placenta in only minimal amounts. Therefore, the levothyroxine added to the block-and-replace regimen maintains maternal euthyroidism but provides essentially no benefit to the fetus — the fetus receives the full suppressive thionamide effect without corresponding thyroid hormone supplementation. The result is higher cumulative fetal thionamide exposure and increased risk of fetal hypothyroidism and fetal goiter. The correct approach in pregnancy is to use the lowest effective thionamide dose that maintains maternal free T4 in the upper third of the normal reference range, with frequent dose adjustments.

Option A: Option A is incorrect: there is no clinically significant pharmacokinetic interaction between PTU and levothyroxine causing accelerated PTU metabolism; the contraindication is pharmacological and placental, not pharmacokinetic.
Option B: Option B is incorrect: levothyroxine does not cross the placenta in large amounts — in fact, the opposite is true; its minimal placental transfer is precisely why block-and-replace is dangerous in pregnancy, as the fetus cannot benefit from the added levothyroxine.
Option C: Option C is incorrect: postpartum thyroid storm from levothyroxine withdrawal is not a recognized consequence of block-and-replace therapy; the contraindication is fetal, not a maternal post-delivery complication.
Option D: Option D is incorrect: block-and-replace is contraindicated in pregnancy and is specifically listed as such in ATA guidelines; it is not the preferred strategy.

21. A 29-year-old woman presents 6 weeks postpartum with palpitations, heat intolerance, and a TSH of 0.08 mIU/L. She had an uncomplicated delivery and is breastfeeding. She has no prior thyroid history. TRAb is negative. The obstetrician diagnoses postpartum thyroiditis in the hyperthyroid phase. Which pharmacological intervention is most appropriate?

A) Methimazole 20-30 mg/day, which should be started promptly in any postpartum woman with TSH suppression to prevent progression to permanent hyperthyroidism and Graves ophthalmopathy.
B) Beta-blockade (such as propranolol) for symptomatic control of palpitations and tremor; antithyroid drugs are not effective in postpartum thyroiditis because thyrotoxicosis results from destructive release of preformed hormone, not from new synthesis.
C) Propylthiouracil (PTU) 100 mg three times daily, which is the agent of choice in breastfeeding women because it inhibits thyroid hormone synthesis and has minimal transfer to breast milk compared to methimazole.
D) Radioactive iodine (RAI) therapy, which should be initiated within 3 months of postpartum thyroiditis diagnosis to prevent the hypothyroid phase that otherwise affects approximately 30% of patients.
E) High-dose prednisone 60 mg/day tapered over 6 months to suppress the autoimmune destructive process and prevent transition to permanent hypothyroidism in this anti-TPO-antibody-positive population.

ANSWER: B

Rationale:

This question asked you to identify the appropriate pharmacological management of the hyperthyroid phase of postpartum thyroiditis. Option B is correct. Postpartum thyroiditis follows a characteristic triphasic course: hyperthyroidism (weeks 1-4 postpartum from destructive release of preformed hormone), hypothyroidism (months 4-8), and return to euthyroidism in most women. The hyperthyroid phase is caused by destructive autoimmune thyroiditis releasing preformed thyroid hormone — there is no ongoing new synthesis. Because antithyroid drugs (methimazole, PTU) work by blocking thyroid hormone synthesis, they have no effect on the hyperthyroid phase of postpartum thyroiditis and are not indicated. Symptomatic management with beta-blockers to control palpitations and tremor is the appropriate pharmacological approach for women symptomatic enough to require treatment; many patients require only observation.

Option A: Option A is incorrect: methimazole is ineffective in the hyperthyroid phase of postpartum thyroiditis because the thyrotoxicosis is not synthesis-driven; starting a synthesis-blocking drug for destructive thyroiditis would provide no benefit while exposing the patient to drug-related risks.
Option C: Option C is incorrect: PTU shares the same limitation as methimazole — it blocks synthesis, which is not the driver of thyrotoxicosis in postpartum thyroiditis; neither thionamide is indicated for this condition's hyperthyroid phase.
Option D: Option D is incorrect: RAI is not indicated in postpartum thyroiditis; the condition is transient and self-limited in the majority of patients, and the destructive gland of postpartum thyroiditis has reduced RAI uptake; using RAI in a self-limiting condition in a breastfeeding woman would be inappropriate.
Option E: Option E is incorrect: glucocorticoids are used in type 2 AIT (amiodarone-induced destructive thyroiditis) but are not standard therapy for postpartum thyroiditis; and high-dose long-term prednisone does not prevent permanent hypothyroidism in postpartum thyroiditis, which is determined by pre-existing autoimmune damage rather than being preventable by steroid therapy.

22. A neonate is born to a mother with Graves disease who has been well-controlled on propylthiouracil (PTU) throughout pregnancy. Maternal TRAb (TSH receptor antibody) measured at 28 weeks was 4.2 times the upper reference limit. The neonate appears clinically euthyroid at birth and the newborn screen TSH at 48 hours is normal. The pediatrician plans to discharge the infant at 48 hours. Which of the following best explains why this plan may be premature?

A) Neonatal Graves disease may present with a 3-7 day delay after birth because the protective effect of maternal antithyroid drugs clears over the first few days of life, after which TRAb-driven thyroid stimulation becomes clinically apparent — a normal 48-hour TSH does not exclude delayed-onset neonatal thyrotoxicosis.
B) The normal 48-hour TSH definitively excludes neonatal Graves disease because TRAb-mediated TSH suppression would be apparent at birth if maternally transferred antibodies were present at pathological levels.
C) Neonatal Graves disease is excluded when maternal TRAb is below 5 times the upper reference limit; since this mother's TRAb is 4.2 times the upper limit, the neonate is at negligible risk and standard discharge timing is appropriate.
D) The delay in neonatal Graves presentation is due to delayed placental transfer of TRAb, which does not reach fetal circulation until 5-7 days after delivery via colostrum; early discharge is therefore safe since TRAb is not yet in the neonate's system.
E) Neonatal Graves disease can only occur if the mother has active hyperthyroidism at the time of delivery; since this mother is well-controlled on PTU, her TRAb is no longer clinically active and poses no risk to the neonate.

ANSWER: A

Rationale:

This question asked you to explain the characteristic delayed presentation of neonatal Graves disease and why a normal 48-hour TSH does not exclude the diagnosis. Option A is correct. Neonatal Graves disease results from transplacental transfer of maternal TRAb. When the mother is on antithyroid drugs at delivery, those drugs — which cross the placenta readily — suppress neonatal thyroid function in utero and for several days after birth. As maternal PTU clears from the neonatal circulation over the first 3-7 days of life, the ongoing TRAb stimulation of the neonatal thyroid becomes unmasked and thyrotoxicosis emerges. A normal TSH at 48 hours does not exclude this condition; the onset of clinical thyrotoxicosis may be delayed until days 3-7. Elevated maternal TRAb above 3 times the upper reference limit at 28-32 weeks is the threshold for significant neonatal risk and should prompt close monitoring including repeat thyroid function testing at 7-10 days of life. This mother's TRAb at 4.2 times the upper limit exceeds that threshold.

Option B: Option B is incorrect: TRAb-mediated suppression of the neonatal pituitary-thyroid axis is exactly why TSH may be normal or even elevated at birth when maternal antithyroid drugs are masking the TRAb effect; a normal 48-hour TSH in this context is not reassuring evidence against neonatal Graves.
Option C: Option C is incorrect: the threshold for elevated neonatal risk is TRAb above 3 times the upper reference limit, not 5 times; this mother's TRAb at 4.2 times the upper limit is above the monitoring threshold and warrants close follow-up regardless of discharge timing.
Option D: Option D is incorrect: TRAb is transferred transplacentally during pregnancy, not postnatally via colostrum; the antibodies are already in the neonatal circulation at birth — the delay in clinical presentation is caused by clearance of maternal antithyroid drug masking the TRAb effect, not by delayed antibody arrival.
Option E: Option E is incorrect: TRAb can persist for years after thyroid ablation or after achieving drug-controlled euthyroidism; a mother who is well-controlled on PTU may still have high circulating TRAb levels, and the neonate is at risk based on TRAb titer regardless of the mother's current thyroid status.